Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Haematological malignancies

2417 - Evaluation of safety, tolerability and efficacy of Temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice


21 Oct 2018


Poster Discussion session - Haematological malignancies


Cytotoxic Therapy

Tumour Site



Martin Dreyling


Annals of Oncology (2018) 29 (suppl_8): viii359-viii371. 10.1093/annonc/mdy286


M.H. Dreyling1, G. Hess2, M. Woike3, G. Krekeler3

Author affiliations

  • 1 Medizinische Klinik Iii, Ludwig Maximilians University - Grosshadern, 81377 - Munich/DE
  • 2 Iii. Medizinische Klinik, Universitätsmedizin der Johannes Gutenberg-Universität, 55101 - Mainz/DE
  • 3 Medical Affairs, Pfizer - Germany, 10785 - Berlin/DE

Abstract 2417


Temsirolimus (TEM), an mTOR inhibitor, is approved in the EU for the treatment of pts with rel/refr MCL. A pivotal study demonstrated significantly longer progression free survival (PFS) with TEM (175 mg weekly for 3 weeks followed by 75 mg weekly) in rel/refr MCL pts compared to investigatoŕs choice therapy (4.8 vs 1.9 months (mo); P = .0009, HR 0.04). To evaluate safety and efficacy of TEM in this rare tumor entity, further collection of data in a post-approval prospective non-interventional trial is useful.


A German multicenter registry for rel/refr MCL pts treated with TEM was started in Germany in Oct 2009 (NCT00700258). Objectives are the evaluation of safety, tolerability and anti-tumor activity of TEM as well as patient's profile including comorbidities, characteristics, and the sequence of systemic therapies.


From Oct 2009 to Feb 2018, 56 pts were recruited in 31 study sites. Baseline characteristics are available for 56 pts: 69.6% male; median age 74.4 years; ECOG PS 0 or 1 in 83.6%, PS 2 in 16.4%. According to MIPI score (n = 54), 20.4%, 33.3%, and 46.3% are classified as low, intermediate, and high risk at the time of enrollment. Median number of prior therapies is 2 with 44.7% treated in ≥ 4th line. Drug related adverse and serious adverse events are observed in 67.9% and 12.5% of pts, respectively. Most common drug-related toxicities of any grade (incidence ≥ 15%) in the following categories: blood/lymphatic system disorders (48.2%), gastrointestinal disorders (28.6%), general disorders (23.2%), and skin/subcutaneous tissue disorders (17.9%). Efficacy analyses are available for 40 assessable pts with an objective response rate (ORR) of 30%, a clinical benefit rate of 60% and PD in 40% of the pts. Median PFS for all pts is 3.7 mo and for pts who achieved an OR with TEM 6.3 mo. Median OS for all pts is 14.8 mo.


The registry was started to evaluate the safety and efficacy of TEM in pts with rel/refr MCL in routine clinical practice. 46.3% high-risk pts were included in the analysis. In this poor-prognosis patient population, TEM showed a predictable, manageable tolerability profile. Efficacy parameters were consistent with published phase III data.

Clinical trial identification


Legal entity responsible for the study

Pfizer Pharma GmbH.


Pfizer Pharma GmbH.

Editorial Acknowledgement


M. Woike, G. Krekeler: Employee: Pfizer Pharma GmbH. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.